Gene essentiality landscape and druggable oncogenic dependencies in herpesviral primary effusion lymphoma

Area of Science:

• Oncology
• Virology
• Genetics

Background:

• Primary effusion lymphoma (PEL) is an aggressive non-Hodgkin lymphoma associated with Kaposi's sarcoma-associated herpesvirus (KSHV).
• Current understanding of PEL pathogenesis and effective treatment strategies remains limited due to its rarity and complexity.
• KSHV infection drives oncogenesis, but specific cellular dependencies driving PEL are not fully elucidated.

Purpose of the Study:

• To comprehensively identify KSHV-driven PEL-specific genetic dependencies using genome-wide CRISPR/Cas9 screening.
• To uncover novel therapeutic vulnerabilities in PEL cell lines and tumors.
• To explore the role of specific cellular and viral factors in PEL maintenance.

Main Methods:

• Genome-wide CRISPR/Cas9 knockout screens were performed across eight distinct PEL cell lines.
• Data integration with unrelated cancer datasets was utilized to pinpoint PEL-specific oncogenic dependencies.
• Expression analysis and drug sensitivity assays were conducted to validate key findings.

Main Results:

• The study identified 210 genes as PEL-specific oncogenic dependencies, largely independent of Epstein-Barr virus co-infection.
• Key dependencies identified include IRF4, MDM2, cellular cyclin D2, c-FLIP, and high MCL1 expression.
• PEL cell lines demonstrated significant sensitivity to palbociclib and S63845, targeting cyclin D2 and MCL1, respectively.

Conclusions:

• This research comprehensively maps the genetic landscape of PEL, revealing critical cellular dependencies.
• The identified dependencies, particularly on cyclin D2 and MCL1, offer promising novel therapeutic targets for PEL treatment.
• Targeting these vulnerabilities may lead to more effective therapeutic interventions for patients with primary effusion lymphoma.